Vaccines miss their mark in seasonal flu campaign

Each year vaccine makers create a cocktail of antigens designed to stand guard against the various versions of the flu making the rounds in winter. But this year the CDC concludes that most of the influenza B viruses in the U.S. aren't being stopped by the vaccine. Two of the three components in the vaccine aren't aimed the right B targets, it seems. The jab may, though, offer protection against the A versions in circulation.

"Most years, the prediction is very good," Joseph Bresee, an influenza epidemiologist at the CDC, tells the Washington Post. "In 16 of the last 19 years, we have had a well-matched vaccine."

- read the report from the Wall Street Journal

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.